CalciMedica Inc CALC

Healthcare

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

NDAQ:CALC - Post by User

CalciMedica Inc

<< Previous

Bullboard Posts

Next >>

Post by ChargingStockson Jan 13, 2022 10:17am

156 Views

Post# 34312399

Graycliff Exploration on Digging Deeper

Hey. Our partnership with Red Cloud is a lot of fun and they have introduced me and my subscirbers to some great companies...
It was a real pleasure speaking with James Macintosh from Graycliff Exploration - outstanding team, great share structure and project. A great conversation!

https://www.youtube.com/watch?v=vzgUGOn9L7I&t=1s

Andrew
https://themarketmindset.ca/
formerly Supercharged Stocks

<< Previous

Bullboard Posts

Next >>

Canadian psychedelic stock to supply MDMA to Yale